There have been a number of studies using CRISPR–Cas9 to knock out inhibitory receptors such as PD-1, LAG-3 and TIM-3 in cancer-specific T cells, leading to enhanced anti-tumour activity [41,42,43]. The gene discussed is HAVCR2; the disease is neoplasm.